Trial · NCT02332798
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) (Single Dose) | PF-04958242 0.25 mg | 1.920 | Geometric Coefficient of Variation 23 | nanograms per milliliter (ng/mL) | |
| Maximum Observed Plasma Concentration (Cmax) (Single Dose) | PF-04958242 0.475 mg | 3.830 | Geometric Coefficient of Variation 21 | nanograms per milliliter (ng/mL) | |
| Cmax (Steady State) | PF-04958242 0.25 mg | 3.174 | Geometric Coefficient of Variation 18 | ng/mL | |
| Cmax (Steady State) | PF-04958242 0.475 mg | 7.139 | Geometric Coefficient of Variation 37 | ng/mL | |
| Time for Cmax (Tmax) (Single Dose) | PF-04958242 0.25 mg | 1.65 | Full Range 1.00 to 2.00 | hours | |
| Time for Cmax (Tmax) (Single Dose) | PF-04958242 0.475 mg | 1.33 | Full Range 0.167 to 3.00 | hours | |
| Tmax (Steady State) | PF-04958242 0.25 mg | 1.65 | Full Range 1.00 to 2.00 | hours | |
| Tmax (Steady State) | PF-04958242 0.475 mg | 1.33 | Full Range 0.50 to 4.00 | hours | |
| Area Under the Concentration-Time Profile From Time 0 to Time Tau (τ), the Dosing Interval, Where τ = 12 Hours (AUCτ) (Single Dose) | PF-04958242 0.25 mg | 9.570 | Geometric Coefficient of Variation 19 | nanograms*hours per milliliter (ng*h/mL) | |
| Area Under the Concentration-Time Profile From Time 0 to Time Tau (τ), the Dosing Interval, Where τ = 12 Hours (AUCτ) (Single Dose) | PF-04958242 0.475 mg | 17.72 | Geometric Coefficient of Variation 18 | nanograms*hours per milliliter (ng*h/mL) | |
| AUCτ (Steady State) | PF-04958242 0.25 mg | 24.57 | Geometric Coefficient of Variation 19 | ng*h/mL | |
| AUCτ (Steady State) | PF-04958242 0.475 mg | 50.09 | Geometric Coefficient of Variation 34 | ng*h/mL | |
| Apparent Oral Clearance (CL/F) (Steady State) | PF-04958242 0.25 mg | 169.5 | Geometric Coefficient of Variation 18 | milliliter per minute (mL/min) | |
| Apparent Oral Clearance (CL/F) (Steady State) | PF-04958242 0.475 mg | 157.9 | Geometric Coefficient of Variation 34 | milliliter per minute (mL/min) | |
| Apparent Volume of Distribution (Vz/F) (Steady State) | PF-04958242 0.25 mg | 545.7 | Geometric Coefficient of Variation 31 | Liter (L) | |
| Apparent Volume of Distribution (Vz/F) (Steady State) | PF-04958242 0.475 mg | 530.2 | Geometric Coefficient of Variation 26 | Liter (L) | |
| Terminal Half-Life (t1/2) (Steady State) | PF-04958242 0.25 mg | 39.64 | Standard Deviation 14.878 | hours | |
| Terminal Half-Life (t1/2) (Steady State) | PF-04958242 0.475 mg | 42.18 | Standard Deviation 14.421 | hours | |
| Observed Accumulation Ratio (Rac) (Steady State) | PF-04958242 0.25 mg | 2.524 | Geometric Coefficient of Variation 20 | Ratio | |
| Observed Accumulation Ratio (Rac) (Steady State) | PF-04958242 0.475 mg | 2.815 | Geometric Coefficient of Variation 31 | Ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02332798/results